Previous 10 | Next 10 |
Gilead Sciences (GILD) has hit the news cycles with reports of a $21 billion deal to buy Immunomedics (IMMU). The massive deal involves $15 billion of cash on hand and $6 billion in new debt. The company already spent $3.1 billion net this year on its Forty Seven acquisition. We expect the m...
Gainers: Immunomedics (NASDAQ: IMMU ) +100% . More news on: Immunomedics, Inc., Cassava Sciences, Inc., Vaxart, Inc., Stocks on the move, , Read more ...
The Nasdaq Composite (NASDAQINDEX: ^IXIC) has finally faced some struggles over the past week or so, but Monday morning seemed to bring some respite for the benchmark index. Greater optimism about the potential for a COVID-19 vaccine helped to bolster sentiment among investors. That helped s...
Shares of cancer specialist Immunomedics (NASDAQ: IMMU) rose by an astounding 106.4% in pre-market trading Monday morning. The biotech's shares are ripping higher this morning in response to a $21 billion buyout agreement with industry giant Gilead Sciences (NASDAQ: GILD) . Gilead report...
Immunomedics (NASDAQ: IMMU ) +106% after Gilead to buy the company for $21B (~$88/share). More news on: Immunomedics, Inc., Cassava Sciences, Inc., China Natural Resources, Inc., , Stocks on the move, Read more ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Merger Monday U.S. stock index futures are shooting for a comeback after the tech-heavy Nasdaq ended its worst week since March. The...
Gilead Sciences ' (NASDAQ: GILD) mission to create a better oncology portfolio took a big step forward on Sunday. The company best known for antiviral treatments made Immunomedics (NASDAQ: IMMU) a juicy buyout offer that values the recently successful cancer drug developer at $21 billion....
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Immunomedics, Inc. (NASDAQ: IMMU) to Gilead Sciences, Inc. for $88.00 per share is fair to Immunomedics shareholders. On behalf of Immunomedics shareholders, Halper Sadeh LLP may seek increased consid...
As expected , Gilead Sciences (NASDAQ: GILD ) agrees to acquire Immunomedics (NASDAQ: IMMU ) in a transaction that values Immunomedics at ~$21B, giving Gilead Trodelvy, which is used to treat certain forms of breast cancer and being evaluated for a number of other cancers. More new...
-- Gilead Adds Trodelvy TM , First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors -- -- Acquisition Transforms Gilead’s Portfolio with First-in-Class Commercial Pro...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...